Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Debt (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Total Debt for 4 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt changed N/A to $8.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.7 million, a N/A change, with the full-year FY2021 number at $1.3 million, down 1.94% from a year prior.
  • Total Debt was $8.7 million for Q3 2025 at Vivos Therapeutics, up from $7.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $8.7 million in Q3 2025 to a low of $1.3 million in Q4 2021.